Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline has initiated a phase II trial to evaluate its experimental anticancer drug Tykerb for the treatment of breast cancer that has metastasized to the brain.
Subscribe to our email newsletter
Tykerb is an orally bio-available small molecule which potently inhibits, two receptors, ErbB2 and ErbB1, and is currently in development as a first-line treatment for ErbB2-overexpressing breast cancer.
Several centers, first in the US and then throughout the world, will begin enrolling patients with breast cancer who have progressive brain metastases following cranial radiotherapy and prior Herceptin-based therapy.
Central nervous system disease progression is emerging as a significant clinical problem in this patient population. Preliminary evidence of activity with Tykerb has been observed in ongoing clinical trials which have enrolled patients with ErbB2-overexpressing breast cancer brain metastases.
“This clinical trial, specifically in patients with brain metastases resulting from breast cancer, is unprecedented and underscores our continued dedication to discovering new treatment options for even the most difficult-to-treat malignancies,” said Dr Paolo Paoletti, senior vice president of the Oncology Medicine Development Center, at GSK.